PT-141 Research for Erectile Dysfunction
An evidence-based overview of research examining PT-141 in the context of erectile dysfunction. This page synthesizes findings from peer-reviewed literature.
Research Summary
PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women but has been studied for erectile dysfunction in men. The drug acts through melanocortin-4 receptors in the central nervous system rather than vascular mechanisms like PDE5 inhibitors. Phase 2 trials showed efficacy in men with ED, including those who didn't respond to sildenafil. The central mechanism offers a different approach for patients who fail conventional ED treatments. PT-141 was not approved for male ED; FDA approval was granted for female HSDD (as Vyleesi). The intranasal formulation that was tested for ED caused blood pressure increases and was not pursued.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Erectile Dysfunction
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. PT-141 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.